The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward human-biology-based testing methods for monoclonal antibody programs. The ...

New data hub will accelerate development and adoption of human-based New Approach Methodologies The NYU Langone-Sage ...

A research team at NYU Langone Health and Sage Bionetworks has been awarded a $25 million grant to establish the data hub and coordinating center for the National Institutes of Health's ...

The very first patient would receive the first clinical doses of HMBD-001, the first cancer treatment from Hummingbird Bioscience. Piers Ingram, the cofounder and CEO of the company, was nervous, but ...

Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational ...

The Green Revolution of the 1950s and 1960s dramatically increased yields and secured the global food supply for a rapidly ...

TORONTO and SAN FRANCISCO, March 17, 2026 /PRNewswire/ - Dalriada Drug Discovery ("Dalriada"), a partnered discovery organization supporting small-molecule programs from hit identification through ...

In a single experiment, scientists can decipher the entire genomes of many patient samples, animal models, or cultured cells.

The FDA’s recent announcement to reduce, and in some cases replace, animal testing for monoclonal antibodies and other therapeutics represents one of the most consequential regulatory developments in ...

The tale of this heartbroken tech entrepreneur, his tumour-riddled rescue dog and a cure for cancer has leading scientists astounded.

Sequential, a leader in genomic testing from non-invasive human clinical samples, today announced the successful close of its first equity round, securing $3.5 million. The round was co-led by ...

Discover how therapeutic peptides act as biological messengers to treat disease, improve metabolism, and enhance immune ...